infusion pumps. This paper ooks at the published data on continuously infused 5-FU in breast cancer. As a single agent, bolus 5-FU has a response rate of around 25%; this inludes many patients in okler series who were chemotherapy naie. The ovall response rate across all the studies with continuously infused 5-FU is 29%. However, the majority of these patients were heavily pretreated, and response rates of up to 54% have been reported. What is more encouraging is the response rate in combination chemotherapy -even for pretreated patients with metastatic diseas, response rates up to 89% have been found. However, this level of benefit brings a new toxicity -pahmar-plantar and of course myelotoxicity still remains a problem in the combination regimens. Randomised trials to assess the role of infusional 5-FU are now indicated.
Fluorouracil (5-FU) has been used in the treatment of breast cancer for over 30 years (Curreri et al., 1958) as adjuvant therapy (Bonnadonna & Valagussa, 1989) as well as in the treatment of metastatic disease (Ansfield et al., 1969) . Used as a single-agent bolus injection, response rates of 25-35% have been reported (Ansfield et al., 1969; Carter, 1976) , whereas in combination with other cytotoxics higher response rates are seen -up to 85% for example with the Duke AFM regimen (Jones et al., 1990) .
5-Fluorouracil is most commonly given as a bolus injection. There has been interest in the prolonged infusion of 5-FU since 1960 (Lemon, 1960; Sullivan et al., 1960) . It was known then that longer infusions produced less toxicity, and so a higher total dose could be administered. This is because of the altered pharmacology of the drug, in particular the clarance is increased (Lemon, 1960; Collins et al., 1980; Fraile et al., 1980) . Furthermore, it has been shown that in patients with metastatic colon cancer, there is a therapeutic benefit of using continuous rather than bolus 5-FU (Lokich et al., 1989) .
Over the past few years there has been increasing interest in the use of 5-FU infusions both intravenously and intraarterially in the treatment of liver metastases, particularly from colon carcinoma. Such infusions have been both continuous, often until progressive disease or toxicity supervenes, or for up to a few days, with a planned break between cycles. Both approaches have been tried for breast cancer, but since it is the prolonged continuous infusions which appear to be associated with the very low myelotoxicity, this review will confine its discussion to the clinical experience of this latter approach.
Badcgro_ 5-Fluorouracil was synthesised in 1957 by Heidelberger et al. (1957) . It was noted a few years earlier that rat hepatomas use uracil as a substrate whereas normal cells do not, and it was postulated that a fluorinated pyrimidine might therefore be taken up selectively into neoplastic cells and be toxic to them. The first clinical studies were arbitrarily done with the drug being given over 5-8 days, somewhat ironic in view of the recent resurgent interest in infusional rather than bolus administration of the drug! The dose was ministered until 35 patients had toxicity, and overall nine responses were noted, particularly in colon and breast carcinoma (3/5 for the latter) (Curreri et al., 1958) .
There are a number of good reviews of the pharmacology of 5-FU (Pinedo & Peters, 1988; Grem, 1990) , but a brief mention of its mode of action will illustrate the arguments for using prolonged infusions in the treatment of cancers. There are two main pathways for the incorporation of 5-FU into nucleic acids. It is metabolised initially to nucleotides including fluoridine 5'-triphosphate (FUTP) and 5-fluoro-2' deoxyuridine-5'-monophosphate (FdUMP), although it is unclar which is the most important pathway clinically (Grem, 1990) . 5-Fluorouracil is inactivated initially by conversion to 5-fluorodihydrouracil (see Figure 1 ) by the enzyme dihydropyrimidine dehydrogenase (DHPD) (Woodcock et al., 1980) . This occurs in all tissues, but its activity is most intense in the liver (Pinedo & Peters, 1988) , which therefore plays a major role in the degradation of 5-FU.
There have been case reports of severe 5-FU toxicity, associated in some cases with an inherited DHPD deficiency (Harris et al., 1991) ; such a deficiency has been shown to result in reduced 5-FU clarance (Etienne et al., 1992) . In the clinical series discussed below, there is a noticeable variation in the toxicity, and this could in part be due to inter-patient variation in the metabolism of 5-FU.
T'he inhibition of thymidylate synthase (TS) is undoubtedly one of its main mechanisms of action, since this leads to depletion of TMP and thus inhibition of DNA synthesis. In the presence of 5,10-CH2-tetrahydrofolate (THF) the efficacy of 5-FU by the concomitant administration of folinic acid (leucovorin). The other main mechanism of the action of 5-FU is via its incorporation into RNA, after conversion to FUTP. The nuclear RNA is then processed into cytoplasmic rRNA, and this probably also contributes to its cytotoxicity (Pinedo & Peters, 1988) .
Administration of a bolus of 5-FU at a dose of between 300 and 600 mg m2 has been extensively studied (Collins et al., 1980) . There is a P half-life of 10-20 min, with rapid elimination, with up to 50% hepatic extraction (Ensminger et al., 1978) . Total clearance is 0.5-21min-'. This results in plasma levels above 1 gM for only a few hours, and this is the level of normal cell toxicity (Cohen et al., 1974) . In contrast, continuous infusion of 5-FU results in a much higher clearance of 2-61min ', which exceeds the hepatic blood flow. This is explained by a high pulmonary extraction (Collins et al., 1980) .
There are perhaps two main reasons to consider using 5-FU in protracted infusion. The first is that, like other antimetabolites which are specific for the S phase of the cell cycle, 5-FU probably exerts much of its cytotoxicity only in dividing cells. Most cancers are heterogeneous in respect of mitotic activity, probably owing to differing numbers in Go (Fisher et al., 1983) . Thus to catch as many cells as possible in S phase, prolonged infusion would seem to be optimal (Vogelzang, 1984) . Secondly a drug with a short-half life, such as 5-FU, would require long-term infusion to permit effective concentrations to be present in the malignant cells at the time of replication (Vogelzang, 1984) . Lokich et al. (1981) was one of the first to develop continuous 5-FU in clinical practice and, like Sullivan et al. in 1960, found that it was no longer myelotoxicity that was dose limiting -rather stomatitis and a new syndrome of palmar-plantar erythrodysaesthesia (PPE) (Lokich & Moore, 1984) . Fraile et al. (1980) showed that a 96 h infusion of 5-FU resulted in 50-to 1,000-fold lower plasma and bone marrow concentrations of the drug, as compared with similar doses administered as an intravenous bolus, which may explain the reduced myelotoxicity. Continuous infusion also permitted the administration of larger total doses of drug (Lokich et al., 1981) .
Clia s
Single-agent use The first published data on the use of continuous 5-FU in the treatment of breast cancer came in a report of four patients among 23 treated by Caballero et al. (1985) with 300 mg m2 day-'. Two partial responses were seen. Toxicity was only briefly discussed (see Table I ) and significant toxicity was managed by a 5 day holiday from treatment; a second such break in treatment prompted a dose reduction of 10-20%.
Hansen et al. (1987) Table I ). Table I ). Toxicity was considerable (see Table I ), and included three patients with ataxia that took 4 weeks to resolve, unlike the other epithelial toxicities, which resolved within 2 weeks. Jabboury et al. (1989a) reported on 36 patients treated initially with 250mgm2, of whom 32 were evaluable for response. All had had prior 5-FU exposure, and, in comparison with the other series, the patients were more heavily pretreated. There was an overall response rate of only 16%. Toxicities were similar to the other studies (see Table I ). However, two patients suffered haemolysis (with a positive direct Coombs test) and the authors noted a progressive rise in the median erythrocyte mean cell volume from 97 fl before treatment to a maximal of 104 fl. Reductions of 50 mg m2 were instituted for toxicity requiring a break in treatment, but equally the dose was increased by 50 mg m-2 if there was no significant toxicity after 4 weeks. Following an initial prevalence of mucocutaneous toxicity of 68%, an elective interruption of treatment for 3-7 days every 4 weeks was instituted for the final 11 patients in the study. Only one of these patients developed oral mucositis, a difference that was highly significant (P = 0.002). Table I .
Our own experience with continuous 5-FU mirrors the later, less optimistic reports (Ng et al., 1994) . We treated 23 patients with metastatic breast cancer, 20 of whom had had previous chemotherapy. Partial responses were seen in eight (35%) of the patients, with a median duration of 12 weeks. Responses were particularly seen in locoregional disease -9/11 patients had some form of response, but only three (25%) met criteria for partial response. Toxicity was generally less than in many reported series (see Table I ).
As can be seen from these studies, PPE is a major toxicity with prolonged infusional 5-FU, but there is some evidence that it can be ameliorated by the use of high-dose pyridoxine. In a study of folinic acid potentiation of weekly 5-FU for patients with metastatic cancer, including five with breast cancer, Mortimer and Anderson (1990) found a prevalence of PPE of 27%. Eleven out of 14 of these patients were treated with oral pyridoxine 150 mg daily, and in all the symptoms resolved within 1 week. There was no loss of tumour response in those given pyridoxine; indeed, the authors noted that they were able to avoid dose reductions of the 5-FU. The rationale for this is the observation that the clinical appearance was similar to that of acrodynia in pyridoxal phosphate-depleted rodents (Gyorgy & Eckharck, 1939) . This was confirmed in a randomised study by Beveridge et al. (1990) , who treated patients with either 100 mg daily or nothing. They noted significant improvement in PPE in the treated patients, but no change in the oral mucositis. However, they saw no fewer dose interruptions for those given pyridoxine, and did not comment on any change in response. (Lokich & Anderson, 1993 . A dose of 250 mg m-2 day-' of 5-FU was given continuously with weekly bolus doxorobicin at 15 mg m2 and cyclophosphamide 70 mg m-2. Doses were altered to obtain a safe nadir, and the 5-FU dose was reduced if grade 2 or higher stomatitis was seen. Twenty-seven of the 37 patients were evaluable, with an overall response rate of 82%, which was not affected by prior chemotherapy. Mucositis was the major dose-limiting toxicity, with 82% having interruptions and dose reductions of the 5-FU to 200 mgm-2 day-'. At this lower dose, no patients had had mucositis after 5 weeks' treatment (see Table II for summary).
In 1988 Strauss et al. reported on 21 previously treated patients. Continuous 5-FU at 300mgm2 day-' was given to all, and ten were also given cisplatinum 20mgm2 week-', for at least 6 weeks. Overall they had 48% partial response rate of 3-15 months' duration, but this was increased to 70% for those also given cisplatinum. Toxicity was 'modest' (see Table H ).
The combination of weekly cisplatinum and etoposide has also been given together with continuous 5-FU at 200 mg m-2 day-' (Saphner et al., 1991) . The CDDP and VP16 were administered weekly as boluses in weeks 2-8, and then fortnightly thereafter. There were at most 12 evaluable patients with breast cancer, including one complete and one partial response. At the dose level they recommended (which was unspecified in the abstract), toxicity was both mucocutaneous and myelosuppression, including grade 4 thrombocytopenia and leucopenia. Percentages were not given.
We have also used a dose of 200mgm2 day-' 5-FU in the treatment of metastatic breast cancer, combining it in a dose-escalating study with doxorubicin (20-30 mg m2 week-') for 12 weeks (Gabra et al., 1993) in a regimen called AcF. A total of 27 patients have been treated to date (55% of whom have been previously treated), and the majority are younger women with visceral metastases. The overall response rate has been 89%, with a complete response rate of 33%, which is higher than that reported for Duke's AFM for the equivalent group of patients (Jones et al., 1990) . Table II summanizes the toxicities seen.
The Royal Marsden Breast Group (O'Brien et al., 1992; Iveson et al., 1993) has combined 200mg m2 day-' continuously infused 5-FU with 60 mg m2 cisplatinum and 50 mg m2 epirubicin administered every 3 weeks, based on the use of same regimen in gastric cancer (Findlay & Cunningham, 1993) . Patients with primary inoperable tumours as well as metastatic disease were included. Table II shows the response rates and toxicities, which are better for the nonmetastatic group (92% vs 75%), although no details of prior chemotherapy are given for the patients with metastatic disease. Significant neurological toxicity was seen (52% for all grades), and included at least one case of ataxia (O'Brien et al., 1992) . Encouraged by these results, the use of this regimen was extended to 6 months of therapy for patients with potentially operable primary breast tumours of at least 3 cm diameter (Smith et al., 1993) . Thirty-four patients were evaluable; all had an objective response, with 22 (65%) exhibiting complete clinical responses. Median time to response was 25 days. Only one patient required a mastectomy at the end of therapy, but the pathological response rate amongst the 15 having wide local excisions was not stated. Severe toxicity (WHO grade 3/4) was acceptable (see Table II ).
In respect of neoadjuvant treatment we have treated patients with T4 Table II ).
ComchHions 5-Fluorouracil has an established role in the treatment of breast cancer, and it is important to determine its best mode of administration. Continuous intravenous administration is obviously feasible with the use of continuous ambulatory electronic pumps, and the reported series had few serious problems with either the semipermanent central lines or the pumps. Single-agent bolus 5-FU does not seem to have much of a role in the treatment of breast cancer (Rubens, 1991) Table II . Obviously what is needed is a comparison, and we are currently undertaking such a randomised study to look at the role of continuous 5-FU within CMF for metastatic breast cancer.
The Marsden group have extended their use of ECF (Smith et al., 1993) to the truly adjuvant situation. This is an interesting development for continuous 5-FU with combination chemotherapy. For patients with poor-prognosis breast cancer at presentation, largely as defined by having >10 positive axillary nodes, it would be interesting to examine the role of regimens such as the Marsden's ECF and our AcF, possibly even as an induction prior to high-dose chemotherapy with stem cell rescue (Peters et al., 1993) . It is, however, probably premature to challenge the gold standard of adjuvant CMF (Henderson & Shapiro, 1991) for those with lower numbers of axillary nodes.
